JP2004500366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500366A5 JP2004500366A5 JP2001548141A JP2001548141A JP2004500366A5 JP 2004500366 A5 JP2004500366 A5 JP 2004500366A5 JP 2001548141 A JP2001548141 A JP 2001548141A JP 2001548141 A JP2001548141 A JP 2001548141A JP 2004500366 A5 JP2004500366 A5 JP 2004500366A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- binding
- polypeptide
- neutralizing antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 36
- 238000000034 method Methods 0.000 description 25
- 241000711549 Hepacivirus C Species 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108010076039 Polyproteins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000008482 12E7 Antigen Human genes 0.000 description 2
- 108010020567 12E7 Antigen Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16823499P | 1999-12-01 | 1999-12-01 | |
| US18505500P | 2000-02-25 | 2000-02-25 | |
| PCT/US2000/042541 WO2001047551A2 (en) | 1999-12-01 | 2000-12-01 | Eliciting antibodies specific for hepatitis c virus (hcv) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500366A JP2004500366A (ja) | 2004-01-08 |
| JP2004500366A5 true JP2004500366A5 (enExample) | 2008-01-10 |
Family
ID=26863907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001548141A Pending JP2004500366A (ja) | 1999-12-01 | 2000-12-01 | Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7329408B2 (enExample) |
| EP (1) | EP1233782B1 (enExample) |
| JP (1) | JP2004500366A (enExample) |
| AT (1) | ATE413190T1 (enExample) |
| AU (1) | AU5442501A (enExample) |
| CA (1) | CA2393251C (enExample) |
| CY (1) | CY1108734T1 (enExample) |
| DE (1) | DE60040755D1 (enExample) |
| DK (1) | DK1233782T3 (enExample) |
| ES (1) | ES2319727T3 (enExample) |
| PT (1) | PT1233782E (enExample) |
| WO (1) | WO2001047551A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1236801A (en) * | 1999-10-27 | 2001-05-08 | Chiron Corporation | Activation of hcv-specific t cells |
| US7329408B2 (en) * | 1999-12-01 | 2008-02-12 | Novartis Vaccines And Diagnostics, Inc. | Eliciting HCV-specific antibodies |
| AUPQ797700A0 (en) * | 2000-06-06 | 2000-06-29 | Austin Research Institute, The | Vaccine |
| AU2002322358B2 (en) * | 2001-06-29 | 2009-06-18 | Novartis Vaccines And Diagnostics, Inc. | HCV E1E2 vaccine compositions |
| CU23244A1 (es) * | 2001-07-16 | 2007-10-17 | Ct Ingenieria Genetica Biotech | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
| CN1582337B (zh) | 2001-10-11 | 2011-12-14 | 默沙东公司 | 丙型肝炎病毒疫苗 |
| AU2003299994A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| US20050191358A1 (en) * | 2003-01-14 | 2005-09-01 | Derek O' Hagan | Microparticles with adsorbed polynucleotide-containing species |
| WO2004071414A2 (en) * | 2003-02-05 | 2004-08-26 | Genzyme Corporation | Therapeutic anti-hcv (al9) compounds |
| US20040203084A1 (en) * | 2003-04-10 | 2004-10-14 | Doug Levinson | Profiling conformational variants, antibody compositions and methods of using the same |
| EP1622566A4 (en) * | 2003-04-25 | 2008-06-25 | Novartis Vaccines & Diagnostic | COMPOSITIONS WITH CATIONIC MICROTEILS AND HCV E1E2 DNA AND METHOD OF APPLICATION THEREOF |
| CA2528007C (en) * | 2003-06-02 | 2012-03-27 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| US20060088819A1 (en) * | 2004-05-17 | 2006-04-27 | Chiron Corporation | Truncated hepatitis C virus NS5 domain and fusion proteins comprising same |
| AU2005294805B2 (en) | 2004-05-28 | 2012-02-16 | Oryxe | A mixture for transdermal delivery of low and high molecular weight compounds |
| PT1801209E (pt) | 2004-08-24 | 2011-05-26 | Toray Industries | Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma |
| DE602005027738D1 (de) * | 2004-11-18 | 2011-06-09 | Univ Hiroshima Nat Univ Corp | Verfahren und kit zur expression von protein unter regulation der expression von einer durch genamplifikation gebildeten wiederholungssequenz und transformant |
| JP5405832B2 (ja) * | 2006-01-04 | 2014-02-05 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | Ｈｃｖ特異的なｔ細胞の活性化 |
| JPWO2009014216A1 (ja) | 2007-07-25 | 2010-10-07 | 国立感染症研究所長 | Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体およびその用途 |
| CN102596996B (zh) | 2009-10-30 | 2014-06-18 | 东丽株式会社 | 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途 |
| CA2856565A1 (en) * | 2010-11-26 | 2012-05-31 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd. | Multimeric hepatitis virus (hcv) envelope 2 (e2) glycoprotein |
| JP6736464B2 (ja) | 2013-08-29 | 2020-08-05 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 細胞透過性コンジュゲート及びその使用の方法 |
| EP3349717A4 (en) | 2015-09-17 | 2019-04-17 | JRX Biotechnology, Inc. | APPROACHES TO IMPROVE SKIN HYDROGENATION OR HUMIDIFICATION |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| EP0318216B2 (en) * | 1987-11-18 | 2001-08-29 | Chiron Corporation | NANBV diagnostics |
| US5471330A (en) | 1993-07-29 | 1995-11-28 | Honeywell Inc. | Polysilicon pixel electrode |
| EP0773957B1 (en) * | 1994-07-29 | 2005-06-29 | Chiron Corporation | Secreted hepatitis C virus E1/E2 complex obtained from C-terminally truncated E1 and E2 polypeptides |
| WO1996004301A2 (en) | 1994-07-29 | 1996-02-15 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| GB9416671D0 (en) | 1994-08-17 | 1994-10-12 | Biocine Spa | Assay |
| US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| EP0862419B2 (en) * | 1995-11-09 | 2010-11-17 | Microbiological Research Authority | Microencapsulated dna for vaccination and gene therapy |
| US5939400A (en) * | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| WO1998050556A2 (en) | 1997-05-06 | 1998-11-12 | Chiron Corporation | Intracellular production of hepatitis c e1 and e2 truncated polypeptides |
| EP0996730A1 (en) * | 1997-07-18 | 2000-05-03 | Connaught Laboratories Limited | Nucleic acid vaccines encoding g protein of respiratory syncytial virus |
| CA2314934C (en) * | 1997-12-16 | 2006-08-29 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
| AU1236801A (en) | 1999-10-27 | 2001-05-08 | Chiron Corporation | Activation of hcv-specific t cells |
| US7329408B2 (en) * | 1999-12-01 | 2008-02-12 | Novartis Vaccines And Diagnostics, Inc. | Eliciting HCV-specific antibodies |
-
2000
- 2000-12-01 US US09/728,423 patent/US7329408B2/en not_active Expired - Lifetime
- 2000-12-01 AT AT00993586T patent/ATE413190T1/de active
- 2000-12-01 WO PCT/US2000/042541 patent/WO2001047551A2/en not_active Ceased
- 2000-12-01 DK DK00993586T patent/DK1233782T3/da active
- 2000-12-01 JP JP2001548141A patent/JP2004500366A/ja active Pending
- 2000-12-01 ES ES00993586T patent/ES2319727T3/es not_active Expired - Lifetime
- 2000-12-01 DE DE60040755T patent/DE60040755D1/de not_active Expired - Lifetime
- 2000-12-01 AU AU54425/01A patent/AU5442501A/en not_active Abandoned
- 2000-12-01 PT PT00993586T patent/PT1233782E/pt unknown
- 2000-12-01 CA CA2393251A patent/CA2393251C/en not_active Expired - Fee Related
- 2000-12-01 EP EP00993586A patent/EP1233782B1/en not_active Expired - Lifetime
-
2007
- 2007-12-13 US US12/001,920 patent/US20080095800A1/en not_active Abandoned
-
2009
- 2009-01-27 CY CY20091100101T patent/CY1108734T1/el unknown
-
2010
- 2010-08-30 US US12/871,035 patent/US20110159039A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500366A5 (enExample) | ||
| CA2393251A1 (en) | Eliciting hcv-specific antibodies | |
| Walayat et al. | Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine | |
| JP2005525085A5 (enExample) | ||
| Lechmann et al. | Vaccine development for hepatitis C | |
| CN105431535A (zh) | 疟疾疫苗 | |
| EP2419124A2 (en) | Foot-and mouth disease marker vaccine | |
| Olivera et al. | Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice | |
| Menne et al. | Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection | |
| RU2639504C2 (ru) | Химерные антигены для вакцины против вируса гепатита с | |
| ES2551113T3 (es) | Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC | |
| Koshy et al. | Evaluation of hepatitis C virus protein epitopes for vaccine development | |
| US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
| Garcia et al. | An overview of hepatitis C vaccines | |
| JP2009522368A5 (enExample) | ||
| CN1984677A (zh) | 截短的丙肝病毒ns5结构域以及含有该截短结构域的融合蛋白 | |
| Alvarez-Lajonchere et al. | Advances in DNA immunization against hepatitis C virus infection: Opportunities and challenges | |
| CN1809584B (zh) | 含有阳离子微粒和hcv e1e2 dna的组合物及其使用方法 | |
| Akbar et al. | Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022; 10: 746 | |
| JP2001517447A5 (enExample) | ||
| Martínez‐Donato et al. | Ratio of HCV structural antigens in protein‐based vaccine formulations is critical for functional immune response induction | |
| Chuai et al. | HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production | |
| Luo et al. | Recent advances in clinical trials of HCV vaccines | |
| Musacchio et al. | Novel knowledge about the influence of hepatitis C virus structural proteins ratio in vaccine preparations to induce a protective immune response in a challenge model with a surrogate virus | |
| Martınez-Donato et al. | Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction |